Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

The top ex­per­i­men­tal drug stem­ming from John­son & John­son’s long-run­ning al­liance with Ad­dex Ther­a­peu­tics has failed a Phase 2 epilep­sy study, cast­ing a shad­ow over its fu­ture.

The can­di­date, ADX71149, did not make a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in time to base­line seizure count when added to the stan­dard of care. Ad­dex is still an­a­lyz­ing the da­ta and will work with its part­ner, J&J, to de­ter­mine the next steps for the pro­gram, Chief Med­ical Of­fi­cer Roger Mills said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER